AzTrials
AzTrials

Cervical CancerPhase 3NCT04422366

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

A Phase 3 study testing 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) and GARDASIL® in people with Cervical Cancer and Vulvar Cancer, run by Shanghai Bovax Biotechnology Co., Ltd. at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years . Read more about this study

Who is it for?
Ages 20 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Cervical Cancer, Vulvar Cancer, Vaginal Cancer
What is being tested?
9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) and GARDASIL®
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8,000 participants
Where
1 siteChina
Study dates
28 Apr 2020to 15 Sep 2029
Phase
Phase 3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • (If the "" option is not met during screening, the visit can be rescheduled)
  • Chinese women aged 20-45 who can provide legal identification and have a sexual life history;
  • The subject fully understands the study procedures, understands the risks and benefits associated with participating in the study, and voluntarily signs the informed consent;
  • Subjects are able to read, understand and fill in application forms such as diary CARDS and contact CARDS, and participate in follow-up according to the study requirements;
  • Subjects have not been screened for cervical cancer, or have been screened for cervical cancer but the results are normal;
  • *0 days before the gynecological visit, no sex within 48 hours, no flushing or vaginal cleaning within 72 hours, no use of vaginal drugs or preparations;Subject agrees to refrain from sexual intercourse (including anal, vaginal, or genital/genital contact of the same or opposite sex) for 48 hours prior to any visit that includes gynecological sample collection, and to refrain from vaginal flushing, vaginal cleansing, or use of vaginal medications or preparations for 72 hours;
  • When the subjects were enrolled, the urine pregnancy test was negative (sensitivity was 25mIU/ml cox-hcg), they were not in the lactation period and had no family planning within 7 months after enrollment (1 month before whole-course inoculation).2 weeks before included in the study, effective contraceptive measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures include: the pill, injection or embedded contraception, slow-release local birth control pills, hormone patch, the intrauterine device (IUD), sterilization, abstinence, condom (men), diaphragm, cervical cap, etc.), rhythm, withdrawal and emergency contraception is unacceptable contraception;
  • *body temperature <37.3℃ (underarm body temperature)

Who cannot join

  • First dose exclusion criteria(If the "" option is met during screening, the visit can be rescheduled)
  • Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine and have received a vaccine/placebo vaccination;
  • Previous positive history of HPV;
  • Has a history of abnormal cervical cytology, including squamous intraepithelial lesions (SIL) or not clear meaning of the atypical squamous cells (ASC - US), except the atypical squamous cells - not highly squamous intraepithelial lesion (ASC - H), atypical glandular epithelial cells, or those with cervical intraepithelial neoplasia (CIN) and carcinoma in situ or abnormal cervical biopsy results such as the history;
  • Past history of anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.);
  • Received total hysterectomy or pelvic radiotherapy;
Show all 39Show fewer
  • Cervical insufficiency or abnormal cervical structure (judged by the results of routine gynecological examination);
  • Previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal) or have obvious condyloma;
  • A history of seizures, convulsions or convulsions, or a family history of mental illness;
  • Have participated in other gynecology-related clinical trials within 6 months, and have used or plan to use other investigational or unregistered products (drugs or vaccines) other than the vaccine in this study within 3 months;
  • A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc.A history of severe adverse reactions to previous vaccinations or a history of severe allergies to any of the components of the vaccine under study (histidine, polysorbate, aluminum phosphate, sodium borate, amorphous aluminum phosphate sulfate adjuvant and water for injection) (such as swelling of the mouth and throat, dyspnea, hypotension or shock, severe urticaria, etc.);
  • Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination, or plans to receive such product within the next 7 months (1 month prior to the full course of vaccination);
  • Subjects present/present with immune impairment or have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;
  • Immunosuppressant therapy within 1 month before the first dose of vaccination, such as long-term use of systemic glucocorticoid therapy (≥2mg/kg/ day, for more than 2 weeks, such as prednisone or similar drugs;Topical administration (such as ointment, eye drops, inhalant or nasal spray) not exceeding the recommended dosage in the directions or showing any signs of systemic exposure) or planning to receive such treatment within the next 7 months (1 month before the full course of inoculation);
  • Absence of spleen or functional absence of spleen, and absence of spleen or splenectomy in any case;
  • Patients with severe liver, kidney and cardiovascular diseases, diabetes or malignant tumor with complications;
  • Patients with thrombocytopenia or any coagulation disorders that may be contraindications to intramuscular injection;
  • * subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated live vaccines within 28 days prior to study enrollment;
  • * an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);
  • * the first dose of vaccine was in pregnancy at the time of vaccination, or the end of pregnancy had not exceeded 6 weeks;
  • * after questioning, subjects had fever symptoms (subaxillary body temperature ≥37.3℃) before the first day of vaccination (within 24 hours before vaccination);
  • * the subject is in the menstrual period;
  • * severe acute vaginitis and suppurative cervicitis found by naked eye during gynecological examination (purulent secretion visible by naked eye);
  • Blood pressure on physical examination before the first dose of vaccination was higher than normal or increased (systolic blood pressure ≥140mmHg and/or diastolic blood pressure ≥90mmHg);
  • Gynecological examination before the first dose of vaccination suspected genital warts, or on the basis of clinical symptoms and signs suspected vulva, vagina or cervical precancerous lesions and the possibility of cancer;
  • Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;
  • In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial, so that continued participation in the study could not guarantee the maximum benefit of the subjects.
  • Second and third doses of vaccine were excluded criteria
  • new discoveries or new occurrences that meet the first dose exclusion criteria (except for articles 2, 3, 4, 21);
  • other serious adverse events: the investigator decides whether to terminate the experimental vaccination according to its treatment needs;
  • the investigator assays for any other reasons that may be considered necessary to terminate the trial vaccination.
  • Second and third doses of vaccine were delayed criteria
  • Vaccination may be postponed if:
  • fever (underarm body temperature ≥37.3℃);
  • before inoculation (on the day of inoculation), the urine pregnancy test was positive (sensitivity was 25mIU/ml n-hcg);
  • acute illness or acute attack of a chronic disease or use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days before vaccination;
  • insufficient interval between other vaccines (inactivated or recombinant vaccines received within 14 days prior to vaccination, or any live attenuated vaccine received within 28 days);
  • any immunoglobulin or blood products received during vaccination should be administered at least 3 months after the vaccination;
  • other circumstances that can be postponed as judged by the researcher.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Yi Mo, Master contact

+8613788686968

moyi0415@qq.com

China1 site, 1 recruiting

  • Liuzhou center for disease control and prevention

    Liuzhou, Guangxi

    Yi Mo, Master

    Recruiting

Other trials in China

About this study

Official title: A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years

This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .

Being tested
9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®
Medical subject headings
Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms, Condylomata Acuminata

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)Biological

    Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.

  • GARDASIL®Biological

    Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule

Study groups in NCT04422366
Study groupRoleWhat they receive
9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52ExperimentalParticipants in this arm would receive 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
Receives: Biological: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
GARDASIL®Active comparatorParticipants in this arm would receive GARDASIL®
Receives: Biological: GARDASIL®

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical abnormalities (CIN 2/3) at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

Secondary outcomes (19)

  1. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related 6-month and 12-month Persistent Infection at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  2. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related VIN 1/2/3, VaIN1/2/3, AIN1/2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  3. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related VIN 2/3, VaIN2/3, AIN2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  4. The person-year incidence of other HPV types related CIN 2/3 at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  5. The person-year incidence of other HPV types related VIN 1/2/3, VaIN1/2/3, AIN1/2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  6. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical abnormalities (CIN 2/3) at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  7. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related 6-month and 12-month Persistent Infection at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  8. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related VIN 2/3, VaIN2/3, AIN2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  9. The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related VIN 1/2/3, VaIN1/2/3, AIN1/2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  10. The person-year incidence of other HPV types related VIN 2/3, VaIN2/3, AIN2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 3

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  11. The person-year incidence of other HPV types related CIN 2/3 at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  12. The person-year incidence of other HPV types related VIN 1/2/3, VaIN1/2/3, AIN1/2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  13. The person-year incidence of other HPV types related VIN 2/3, VaIN2/3, AIN2/3, vulvar cancer, vaginal cancer and anal cancer at least 1 month post Dose 1

    Measured: 1 month post vaccination 1 up to Month 84

  14. Percentage of Participants Who Report at Least 1 Solicited Injection-site and Systemic Adverse Event 30 minutes post any vaccination

    Measured: 30 minutes post any vaccination

  15. Percentage of Participants Who Report at Least 1 Solicited Adverse Event 7 days post any vaccination

    Measured: 7 days post any vaccination

  16. Percentage of Participants Who Report at Least 1 Solicited and Unsolicited Adverse Event 30 days post any vaccination

    Measured: 30 days post any vaccination

  17. Percentage of Participants Who Experience at Least 1 Serious Adverse Event (SAE) from 1st vaccination to the completion of study

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  18. Percentage of Participants Who Experience Pregnancy from 1st vaccination to the completion of study

    Measured: 1 month post vaccination 3 (Month 7) up to Month 84

  19. neutralizing antibody level

    Measured: 30 days post third dose of vaccination

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jun 2020
  2. Study start28 Apr 2020
  3. Primary completion15 Sep 2027 (estimated)
  4. Study completion15 Sep 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
8,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04422366
Sponsor's protocol ID
9-HPV-3001
Status last verified
Apr 2024
First submitted
17 May 2020
Last updated
7 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) and GARDASIL® in people with Cervical Cancer and Vulvar Cancer, run by Shanghai Bovax Biotechnology Co., Ltd. at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 7 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yi Mo, Master (+8613788686968, moyi0415@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The person-year incidence of HPV 31-, 33-, 45-, 52-, and 58-related high-grade cervical abnormalities (CIN 2/3) at least 1 month post Dose 3 (time frame: 1 month post vaccination 3 (Month 7) up to Month 84). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04422366.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jun 2024.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in